Join Our Mailing List:
 
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
310-841-2600
Featured Events
Sunday, October 15
8th Annual STOP CANCER 5|10K Run|Walk
On your mark, get set, go! Be part of the 8th Annual 5|10K Run|Walk ... More
View All Events
Thanh H. Dellinger
Research performed at: City of Hope Comprehensive Cancer Center
Specialty/Research Area: Gynecologic Oncology, Novel therapies for uterine/endometrial
Award Year: 2017
Career Summary: Thanh Dellinger, MD, is an Assistant Professor in the Department of Surgery, Division of gynecologic Oncology at City of Hope. She received her M.D. in 2004 from the University of California, Irvine School of Medicine, and went on to Penn State University to complete an OB/GYN residency. She then returned to University of California, Irvine Medical Center and Chao Comprehensive Cancer Center for a four-year gynecologic oncology fellowship. During this time, she researched the pathogenesis of endometrial cancer, and further elucidated the role of Wnt signaling in this disease. Dr. Dellinger became an Assistant Professor at City of Hope in 2012, and has since focused on developing novel therapies for ovarian and endometrial cancers, including nanoparticle delivered stem cell therapies and targeted immunotherapies. Dr. Dellinger has been awarded a Foundation for Women’s Cancer award in 2013, and an Ovarian Cancer Research Foundation grant in 2014.  

Year STOP CANCER Award received: 2017 Seed Grant in gynecological malignancies

Description of research performed: endometrial cancer remains an understudied and underfunded cancer, despite a poor prognosis for patients with advanced and recurrent disease.  Our group is developing a targeted immunotherapeutic to treat high-risk endometrial cancer.  We and others have shown that L1CAM is a novel biomarker for endometrial cancer, and a potential target for novel personalized therapy in this population. Such targeted therapy can be developed via antibody technology to create a masked antibody against L1CAM, which will additionally generate an immune response within the patient to kill the tumor. 

STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2017 STOP CANCER. All Rights Reserved. | Privacy Policy